Premium
Urinary tract infections caused by ESBL ‐producing Enterobacteriaceae in renal transplant recipients: A systematic review and meta‐analysis
Author(s) -
Alevizakos Michail,
Nasioudis Dimitrios,
Mylonakis Eleftherios
Publication year - 2017
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12759
Subject(s) - medicine , confidence interval , meta analysis , urinary system , incidence (geometry) , renal transplant , transplantation , physics , optics
Abstract Background Urinary tract infections ( UTI s) are the most common infectious complications among renal transplant recipients ( RTR ). UTI s caused by extended‐spectrum beta‐lactamase ( ESBL )‐producing Enterobacteriaceae ( ESBL ‐ PE ) have been associated with inferior clinical outcomes and increased financial burden. Methods We performed a systematic review and meta‐analysis by searching through the PubMed and EMBASE databases (to May 20, 2016) and identifying studies that reported data on the number of RTR who developed an ESBL ‐ PE UTI . Results Our analysis included seven studies, out of 357 non‐duplicate articles, that provided data on 2824 patients. Among them, 10% (95% confidence interval [ CI ] 4%‐17%) developed an ESBL ‐ PE UTI over their follow‐up periods. The proportion of RTR affected by an ESBL ‐ PE UTI was 2% in North America (95% CI 1%‐3%), 5% in Europe (95% CI 4%‐6%), 17% in South America (95% CI 10%‐27%), and 33% in Asia (95% CI 27%‐41%). In addition, patients affected with an ESBL ‐ PE UTI were 2.75‐times (95% CI 1.97‐3.83) more likely to suffer a recurrent UTI . Conclusions Based on a limited number of studies, one in 10 RTR will develop a UTI caused by an ESBL ‐ PE , and these patients face an almost 3 times greater risk of recurrence. A more rigorous monitoring of RTR , both during and after resolution of their infection, should be evaluated in order to reduce the incidence and the clinical impact of these resistant infections.